Factor VIII gene variants and inhibitor risk in African American hemophilia A patients-Reference-Cited by-同舟云学术

Factor VIII gene variants and inhibitor risk in African American hemophilia A patients

Published:2015-08-13 Issue:7 Volume:126 Page:895-904
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Gunasekera Devi¹²,Ettinger Ruth A.²,Nakaya Fletcher Shelley³,James Eddie A.⁴,Liu Maochang²,Barrett John C.⁵,Withycombe Janice⁶,Matthews Dana C.⁷,Epstein Melinda S.⁸,Hughes Richard J.⁸,Pratt Kathleen P.¹²^ORCID

Affiliation:

1. Uniformed Services University of the Health Sciences, Bethesda, MD;

2. Puget Sound Blood Center Research Institute, Seattle, WA;

3. Genomics Laboratory, Puget Sound Blood Center, Seattle, WA;

4. Benaroya Research Institute, Seattle, WA;

5. Central Virginia Center for Coagulation Disorders, Virginia Commonwealth University, Richmond, VA;

6. Palmetto Health, Columbia, SC;

7. Pediatrics/Cancer and Blood Disorders Center, Seattle Children’s Hospital, Seattle, WA; and

8. Department of Pathology and Laboratory Medicine, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA

Abstract

Key Points Immune responses to FVIII sequence variants encoded by ns-SNPs do not contribute appreciably to inhibitor development in African Americans. African American HA subjects with an intron-22 inversion had a 2- to 3-times-higher inhibitor incidence than whites with the same mutation.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/7/895/1391159/895.pdf

Reference47 articles.

1. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.;Lollar;J Thromb Haemost,2004

2. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis.;Gouw;Blood,2012

3. Mild haemophilia: a disease with many faces and many unexpected pitfalls.;Peerlinck;Haemophilia,2010

4. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.;Gouw;Blood,2013

5. In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study.;Kempton;J Thromb Haemost,2010

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Haemophilia in the era of novel therapies: Where do inhibitors feature in the new landscape?;Haemophilia;2024-03-27

2. Unearthing the genotype‐inhibitor phenotype association in severe haemophilia A: A north Indian cohort study;Haemophilia;2024-02-11

3. Recent Advances in Genetic and Non-Genetic Factors Related to the Development of Hemophilia Inhibitors;Advances in Clinical Medicine;2024

4. Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies;Journal of Pharmaceutical Sciences;2023-09

5. Race, ethnicity, F8 variants, and inhibitor risk: analysis of the “My Life Our Future” hemophilia A database;Journal of Thrombosis and Haemostasis;2023-04